BioCryst Pharmaceuticals investors sell shares, reduce stake to 17.9%

By Lisa Kerner

Charlotte, N.C., June 2 - Julian C. Baker and Felix J. Baker cut their stake in BioCryst Pharmaceuticals, Inc. to 17.9% through the sale of 817,074 shares of the company's common stock between May 28 and June 1 priced from $4.45 to $4.50, according to a schedule 13D/A filed with the Securities and Exchange Commission on Tuesday.

The Bakers beneficially own 7,146,948 shares of the Birmingham, Ala., pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.